China Resources Pharmaceutical Group (HKSE:03320) EV-to-EBITDA : 2.49 (As of May. 21, 2024)

China Resources Pharmaceutical Group EV-to-EBITDA Chart

China Resources Pharmaceutical Group Annual Data
	Trend	Dec14	Dec15	Dec16	Dec17	Dec18	Dec19	Dec20	Dec21	Dec22	Dec23
EV-to-EBITDA		Get a 7-Day Free Trial					6.03	4.49	4.69	5.43	5.14

China Resources Pharmaceutical Group Semi-Annual Data
	Dec13	Dec14	Jun15	Dec15	Jun16	Dec16	Jun17	Dec17	Jun18	Dec18	Jun19	Dec19	Jun20	Dec20	Jun21	Dec21	Jun22	Dec22	Jun23	Dec23
EV-to-EBITDA	Get a 7-Day Free Trial															4.69	-	5.43	-	5.14

Competitive Comparison of China Resources Pharmaceutical Group's EV-to-EBITDA

For the Drug Manufacturers - Specialty & Generic subindustry, China Resources Pharmaceutical Group's EV-to-EBITDA, along with its competitors' market caps and EV-to-EBITDA data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

China Resources Pharmaceutical Group's EV-to-EBITDA Distribution in the Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, China Resources Pharmaceutical Group's EV-to-EBITDA distribution charts can be found below:

* The bar in red indicates where China Resources Pharmaceutical Group's EV-to-EBITDA falls into.

China Resources Pharmaceutical Group EV-to-EBITDA Calculation

China Resources Pharmaceutical Group's EV-to-EBITDA for today is calculated as:

China Resources Pharmaceutical Group's current Enterprise Value is HK$41,943 Mil.
For company reported semi-annually, GuruFocus uses latest annual data as the TTM data. China Resources Pharmaceutical Group's EBITDA for the trailing twelve months (TTM) ended in Dec. 2023 was HK$16,878 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

China Resources Pharmaceutical Group  (HKSE:03320) EV-to-EBITDA Explanation

EV-to-EBITDA is a valuation multiple used in finance and investment to measure the value of a company. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio to determine the fair market value of a company.

China Resources Pharmaceutical Group's PE Ratio for today is calculated as:

China Resources Pharmaceutical Group's share price for today is HK$6.00.
For company reported semi-annually, GuruFocus uses latest annual data as the TTM data. China Resources Pharmaceutical Group's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Dec. 2023 was HK$0.667.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Study has found that the companies with the lowest EV-to-EBITDA outperforms companies measured as cheap by other ratios such as PE Ratio.

Please read Which price ratio outperforms the enterprise multiple?

China Resources Pharmaceutical Group EV-to-EBITDA Related Terms

Thank you for viewing the detailed overview of China Resources Pharmaceutical Group's EV-to-EBITDA provided by GuruFocus.com. Please click on the following links to see related term pages.

China Resources Pharmaceutical Group (HKSE:03320) Business Description